LYON, France--(BUSINESS WIRE)--POXEL SA (Paris:POXEL) (EURONEXT: POXEL), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE DRUGS TO TREAT TYPE 2 DIABETES, TODAY announced that Richard N. Kender has joined the Company’s Board of Directors as an independent Board member. As a driving force behind Merck and Co. Inc.’s corporate development initiatives, Mr. Kender brings POXEL more than 35 years of experience in pharmaceutical licensing and strategic partnerships as well as finance, was most recently the Senior Vice President of Business Development and Corporate Licensing for Merck and Co. Inc.
Help employers find you! Check out all the jobs and post your resume.
